Gastroenteropancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) [Phase 2]
Phase 2 clinical trial evaluating the activity and safety of combining cabozantinib with temozolomide in lung and gastroenteropancreatic neu…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients [Phase 4]
This Phase 4 trial update describes continuing somatostatin analogue therapy in patients with gastroenteropancreatic neuroendocrine tumors a…
-
FDA approval · 2024-05-21FDA Approved: LANREOTIDE ACETATE — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for lanreotide acetate (lanreotide) to treat acromegaly and gastroenteropancreatic ne…
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: Observational Study on GEP-and Pulm-NET Treated at FPG
An observational clinical trial update describes a study of gastroenteropancreatic and pulmonary neuroendocrine tumors treated at Fondazione…
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Surgical Intervention and the NETest [NA]
Clinical trial update for a surgical intervention study using the NETest in neuroendocrine tumors. Sponsor Wren Laboratories LLC indicates t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-05FDA Approved: OCTREOTIDE ACETATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved OCTREOTIDE ACETATE as an original application, enabling a Teva-manufactured generic octreotide acetate.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.
-
FDA approval · 2023-07-27FDA Approved: GA-68-DOTATOC — Supplemental Application (UIHC P E T Imaging Center)
The FDA approved a supplemental application for GA-68-DOTATOC (edotreotide gallium-68) from the UIHC PET Imaging Center to use this radiopha…
-
FDA approval · 2023-06-30FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for octreotide acetate filed by Fresenius Kabi USA, LLC.
-
FDA approval · 2023-03-07FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) submitted by Advanced Accelerator Applications USA, Inc. Th…
-
FDA approval · 2023-02-21FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for octreotide acetate by Mylan Institutional LLC under ANDA 079198, granting a supplemental approva…
-
FDA approval · 2022-06-06FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approves a supplemental application for LUTATHERA (Lutetium Lu-177 dotatate) filed by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2021-12-17FDA Approved: LANREOTIDE ACETATE — Original Application (Cipla USA Inc.)
The FDA approved lanreotide acetate from Cipla USA Inc. as an original application, providing a generic option for the somatostatin analog u…
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) [Phase 2]
Phase 2 trial evaluating the optimal dose of the PET imaging agent 68Ga-OPS202 in gastroenteropancreatic neuroendocrine tumors has completed…
-
FDA approval · 2020-05-29FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) from Advanced Accelerator Applications USA, Inc., grant…
-
FDA approval · 2019-09-05FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for octreotide acetate submitted by Mylan Institutional LLC (ANDA079198). This action constitutes a …
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET [Phase 2]
Phase 2 trial evaluating combination of Lanreotide Autogel 120mg with Temozolomide in progressive gastroenteropancreatic neuroendocrine tumo…
-
FDA approval · 2019-04-11FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
This FDA document indicates approval of a supplemental application for Somatuline Depot (lanreotide acetate) by Ipsen Biopharmaceuticals, In…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor [Phase 2]
The Phase 2 study of famitinib in advanced or metastatic gastroenteropancreatic neuroendocrine tumors has been terminated.
-
FDA approval · 2018-12-12FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., resulting in regu…
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 [Phase 2]
A Phase 2 study evaluating anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3 is ongoing or not yet reported.
-
FDA approval · 2016-07-22FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis Pharmaceuticals Corporation, resulting in…
-
FDA approval · 2015-11-02FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2015-06-01FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) filed by Ipsen Biopharmaceuticals, Inc., updating the …
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: Octreotide LAR as Maintenance Treatment for Patients With NEC [Phase 2]
Phase 2 clinical trial update evaluating Octreotide LAR as maintenance therapy for neuroendocrine carcinomas in the gastroenteropancreatic a…